Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Female Sexual Dysfunction: Lead Agents Are New Formulations Of Marketed Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

Procter & Gamble will likely have the first product to treat hypoactive sexual desire disorder in women with its Phase III testosterone patch Intrinsa. Vivus has late-stage compounds for two major components of female sexual dysfunction: a testosterone spray for hypoactive desire and a topical alprostadil for female sexual arousal disorder.
Advertisement

Related Content

P&G's Intrinsa Priority Review Puts Approval Timeline At Early 2005
P&G's Intrinsa Priority Review Puts Approval Timeline At Early 2005
BioSante Expects Estradiol, Testosterone Gel Filings In 2004; Marketing Will Ride Solvay Coattails
BioSante Expects Estradiol, Testosterone Gel Filings In 2004; Marketing Will Ride Solvay Coattails
Viagra Cannot Perform In Women: Pfizer Ends Female Sexual Arousal Disorder Studies

Topics

Advertisement
UsernamePublicRestriction

Register

PS059425

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel